59. FARMAKOLOGICKÉ DNI V BRATISLAVE 2. – 4. SEPTEMBRA 2009 SUZA, DROTÁRSKA CESTA 9, BRATISLAVA ZOZNAM POSTEROV 1.Internalization of 177Lu‐labeled antibody Nimotuzumab in human cancer cell cultures. PAVEL BARTAa, AL

Source URL: farmspol.cls.cz

Clinical Cancer Research Cancer Therapy: Clinical

Source URL: www.cimab-sa.com

• Oncogenes
• Tyrosine kinase receptors
• Amines
• Quinazolines
• Alkynes
• Epidermal growth factor receptor
• Nimotuzumab
• Zalutumumab
• Cetuximab
• Medicine
• Chemistry
• Biology

Award ID: RP100708 Project Title: Development of a novel anti-EGFR antibody-protamine recombinant protein for in vivo delivery of small interfering RNAs for cancer therapy Award Mechanism:

Source URL: www.cprit.state.tx.us

• Drugs
• Targeted therapy
• Epidermal growth factor receptor
• Head and neck cancer
• Nimotuzumab
• Zalutumumab
• Medicine
• Biology
• Oncology

Description Nimotuzumab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) by interacting with epitope located in the e

Source URL: www.biocon.com

• Nimotuzumab
• Radiation therapy
• Glioma
• Mucositis
• Glioblastoma multiforme
• Cetuximab
• Medicine
• Brain tumor
• Head and neck cancer